Our project start from addressing chronic disease management challenges, particularly related to the "Four Highs," which significantly contribute to coronary heart disease (CHD). Given the burden these diseases place on global healthcare, early detection and continuous monitoring are crucial. In response, we focus on a home-based Point-of-Care Testing (POCT) system to detect key biomarkers like glucose and uric acid. Using synthetic biology, we engineered plasmid-based biosensors that provide accurate, fluorescence-based measurements, reducing recalibration needs and improving the reliability of home diagnostics.

We integrated human practices into every stage of our work, with healthcare professionals, patients, and device manufacturers, etc., we identified key performance specifications that shaped both the bioengineering and hardware components of the system.

Our hardware taskforce worked closely with the bioengineering taskforce to ensure the system met the identified key performance specifications. The hardware design was broken down into six key components: Optical Sensing and Signal Processing, Microfluidic Chip, Temperature Monitoring and Control, Outer Shell, Software and User Interface, and Electronic Circuit Module. Each module was assigned specific Proof of Concept (POC) stage goals, and by the project's end, we successfully achieved the targeted POC milestones for all modules, ensuring seamless integration and functionality with the biosensor platform. Welcome to visit our Booth (T-22 Group A) and we will demostrate our hardware there.

As the project evolved, we expanded the system’s capabilities for multi-biomarker detection by incorporating modularity into both bioengineering and hardware designs. Standardizing the biosensor platform enabled easy addition or replacement of biomarkers. Initially focused on lactic acid, we shifted to tryptophan, showcasing system flexibility. The hardware was designed to detect up to three biomarkers simultaneously through modular, interchangeable components, allowing for customization and broader applications beyond glucose and uric acid monitoring. This combination of flexible biosensors and modular hardware ensures adaptability for future diagnostic needs.